Predicting Ocular Relapse in Sarcoid Uveitis: Macular Edema and Baseline Inflammation as Critical Prognostic Markers
Posted innews Ophthalmology Rheumatology

Predicting Ocular Relapse in Sarcoid Uveitis: Macular Edema and Baseline Inflammation as Critical Prognostic Markers

A multicentric study of 336 patients reveals that two-thirds of sarcoid uveitis cases experience relapse, primarily driven by baseline macular edema and persistent inflammation. Despite high recurrence rates, long-term visual prognosis remains favorable for most, with low rates of severe vision loss over nearly eight years.
Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
Posted inDiabetes & Endocrinology news Rheumatology

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injection burden for high-risk postmenopausal women.
ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups
Posted innews Rheumatology

ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups

The ESTIVAL trial investigated transcutaneous auricular vagus nerve stimulation (taVNS) for erosive hand osteoarthritis. While the primary pain reduction endpoint was not met, the therapy proved safe and showed potential efficacy in patients with significant synovial inflammation, suggesting a need for phenotype-specific research.
Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.